Comparative Pharmacology
Head-to-head clinical analysis: TAXOL versus TAXOTERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAXOL versus TAXOTERE.
TAXOL vs TAXOTERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paclitaxel stabilizes microtubules by binding to the β-tubulin subunit, preventing depolymerization, thereby disrupting mitotic spindle formation, cell division, and intracellular transport.
Taxotere (docetaxel) is a semisynthetic taxane that promotes microtubule assembly and inhibits depolymerization, leading to stabilization of microtubules and disruption of mitotic cell division. This results in cell cycle arrest at G2/M phase and apoptosis in cancer cells.
Intravenous infusion of 175 mg/m² over 3 hours every 3 weeks for ovarian carcinoma; 135 mg/m² over 24 hours every 3 weeks for breast carcinoma; 100 mg/m² over 3 hours every 2 weeks for NSCLC; 175 mg/m² over 3 hours every 2 weeks for AIDS-related Kaposi sarcoma.
75 mg/m² intravenously over 1 hour every 3 weeks.
None Documented
None Documented
Clinical Note
moderateBetaxolol + Digoxin
"Betaxolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateBetaxolol + Digitoxin
"Betaxolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateBetaxolol + Deslanoside
"Betaxolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateBetaxolol + Acetyldigitoxin
"Betaxolol may increase the bradycardic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5.3 to 16.3 hours (mean ~13 hours); exhibits triphasic elimination with a prolonged terminal phase due to extensive tissue binding.
Terminal elimination half-life is approximately 11–13 hours, with a mean of 11.1 hours. This supports a 3-week dosing interval.
Primarily hepatic metabolism via CYP2C8 and CYP3A4; biliary/fecal excretion accounts for ~70% of total clearance; renal excretion is minimal (<10% as unchanged drug).
Following hepatic metabolism, elimination is primarily via biliary/fecal excretion (approximately 75% of dose as metabolites and unchanged drug), with renal excretion accounting for about 10% (primarily as metabolites).
Category C
Category C
Taxane Antineoplastic
Taxane Antineoplastic